Experimentica has appointed Dr. Marc Cerrada-Gimenez as Director, In Vivo GLP Operations, supporting the expansion of its GLP safety and toxicology capabilities in Kuopio, Finland.

Learn more

Experimentica strengthens its position as a leading global ophthalmic CRO by investing in a new GLP‑compliant facility, enabling comprehensive GLP safety and toxicology studies for innovative ocular therapies.

Learn more

Experimentica Ltd., a trusted partner in preclinical drug development for ocular diseases, is pleased to announce the appointment of Teija Parkkari as Director of Business Development, effective April 13, 2026.

Learn more

Experimentica utilizes a validated mouse model of dry eye disease. Dry eye disease-like pathology is induced using transdermal scopolamine patches in combination with desiccating environmental stress. The induced pathology is characterized using corneal fluorescein staining, tear volume measurements, and histology for lacrimal gland infiltration, goblet cell loss, and corneal abnormalities.

Learn more

Experimentica Ltd., a global contract research organization (CRO) dedicated to preclinical models of ophthalmic diseases, announces a significant expansion of its Kuopio site in Finland.

Learn more

A brief overview of streptozotocin-induced diabetic retinopathy in rodents, highlighting strain-specific differences, quantitative assessment of retinal vascular leakage, identification of the most consistent and reliable readout, and animal welfare considerations.

Learn more

At Experimentica, we are committed to advancing R&D and continuously improving established study methods. Our work is guided by three core principles: quality, flexibility, and scientific excellence, all of which support our commitment to be a trusted partner for our clients. In collaboration with Finnadvance Ltd, we validated the AKITA® platform combined with human corneal epithelial cells which has yielded substantial advancements in in vitro corneal permeability studies.

Learn more

Experimentica Ltd., a trusted partner in preclinical drug development for ocular diseases, is excited to announce the appointment of Dr. Artem Shatillo as Director of Digital Transformation, effective July 1, 2025.

Learn more